{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:02:53Z","timestamp":1789448573172,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of Iparomlimab and Tuvonralimab, a PD-1\/CTLA-4 bispecific antibody, in combination with chemoradiotherapy for a patient with microsatellite stable\/mismatch repair proficient (MSS\/pMMR) locally advanced rectal cancer (LARC), and to analyze the mechanism of achieving short-term clinical complete response (cCR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This case report presents a 61-year-old male with stage cT3N2aM0 IIIB MSS\/pMMR rectal cancer. The patient received neoadjuvant therapy with Iparomlimab and Tuvonralimab (300mg per dose) plus XELOX regimen chemotherapy and radiotherapy (45Gy\/25F). Responses were regularly assessed via digital rectal examination, imaging, endoscopy, and pathology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After treatment, clinical complete response (cCR) was initially evidenced by MRI at week 12 and subsequently confirmed by endoscopic assessment combined with pathologic biopsy at week 20. No grade 3 or higher immune-related adverse events occurred. At the last follow-up in March 2026, no recurrence was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case suggests that Iparomlimab and Tuvonralimab combined with chemoradiotherapy may induce rapid cCR in MSS\/pMMR LARC, offering a promising organ-preserving strategy through immunotherapy. Further large-sample studies are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1936564","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:26:38Z","timestamp":1789446398000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: rapid clinical complete response to Iparomlimab and Tuvonralimab combined with radiotherapy and chemotherapy in a patient with MSS\/pMMR locally advanced rectal cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Jue","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[{"name":"Kunming Medical University","place":["Kunming, Yunnan, China"]},{"name":"People's Hospital of Nujiang Lisu Autonomous Prefecture","place":["Lushui, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingrui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyu","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhumadian Central Hospital","place":["Zhumadian, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibiao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"46","author":"Zheng","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0071","article-title":"Adoption of total neoadjuvant therapy for locally advanced rectal cancer","volume":"4","author":"Cercek","year":"2018","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103663","article-title":"Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update","volume":"173","author":"Boukouris","year":"2022","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: A therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-024-01762-y","article-title":"Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12943-024-02166-w","article-title":"Cellular mechanisms of combining innate immunity activation with PD-1\/PD-L1 blockade in treatment of colorectal cancer","volume":"23","author":"Xie","year":"2024","journal-title":"Mol Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2022.10.018","article-title":"Neoadjuvant immunotherapy for dMMR\/MSI-H locally advanced rectal cancer: The future new standard approach","volume":"49","author":"Cabez\u00f3n-Guti\u00e9rrez","year":"2023","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-022-01294-4","article-title":"Exploring immunotherapy in colorectal cancer","volume":"15","author":"Weng","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02261","article-title":"Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH)","volume":"42","author":"Xia","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.015","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial","volume":"35","author":"Lin","year":"2024","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: The Canadian Cancer Trials Group CO.26 Study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-023-01445-1","article-title":"First-in-human phase I\/Ib study of QL1706 (PSB205), a bifunctional PD1\/CTLA4 dual blocker, in patients with advanced solid tumors","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-018-0011-0","article-title":"A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy","volume":"28","author":"Du","year":"2018","journal-title":"Cell Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232101","article-title":"Radiotherapy and immunology","volume":"221","author":"Wang","year":"2024","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2024.10.025","article-title":"Synergizing autophagic cell death and oxaliplatin-induced immunogenic death by a self-delivery micelle for enhanced tumor immunotherapy","volume":"190","author":"Deng","year":"2024","journal-title":"Acta Biomater"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1936564\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:26:41Z","timestamp":1789446401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1936564\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1936564"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1936564","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1936564"}}